Introduction
Oral steroid contraceptives have emerged as a generally well tolerated, reversible, effective form of contraception and are extensively used worldwide. Owing to the pioneering work of Pincus et al. the ®rst combined oral contraceptive (COC) containing 150 mg mestranol and 9.85 mg norethynodrel was developed in the late 1950s (Pincus et al., 1958) . Since the introduction of this ®rst COC, new contraceptive techniques have provided alternative forms of steroid contraception: i.m. depot injections, subdermal implants, intrauterine delivery systems, vaginal rings and transdermal patches. Oral contraceptives (OCs) have evolved through discovery of new progestins, development of progestin-only pills and gradual lowering of the estrogen content in COCs. Biphasic and triphasic regimens appeared by changing the individual dosages for the estrogen and progestin components. All of these efforts are aimed at reducing adverse effects and improving compliance while maintaining superior ef®cacy over non-steroid forms of reversible contraception. However, in reducing the steroid burden to avoid adverse effects, suppression of endogenous hypothalamic±pituitary±ovarian activity could be compromised in cases of pill omissions, during the pill-free period and during co-medication (Fauser and Van Heusden, 1997) . Studies addressing the in¯uence of contraceptive steroids on the hypothalamic±pituitary±ovarian axis can be classi®ed as shown in Table I .
The exact mode of action of contraceptive steroids in COC has not yet been satisfactorily elucidated. The majority of studies describe serum levels of FSH, LH, estradiol (E 2 ) or progesterone, sometimes in combination with ultrasound assessments of follicle diameters during the studied contraceptive medication. Next to these observational studies, knowledge concerning the contraceptive activity of COCs has bene®ted from intervention studies. GnRH, hCG or FSH intervention studies during active medication, pill omissions and the study of the pill-free period have provided critical information regarding contraceptive ef®cacy.
The focus of this review is to summarize the effects of oral steroid contraceptives on residual pituitary±ovarian activity.
Progestins
The classi®cation of progestins is based either on chemical structure (19-nortestosteronederivatives or 17-a-acetoxyprogesteronederivatives), receptor af®nity or`relative' potency. The latter is often derived from their effects on the endometrium (Clauberg or Swyer±Greenblatt test) (Goldzieher, 1986) . However, equipotency in relation to endometrial effects does not imply the same effect on other parameters such as metabolism or LH suppression. Thus the assessed`relative potency' depends upon the target organ and the parameter studied and therefore should not be used.
Progestins are believed to exert their contraceptive effects through a variety of changes in different targets: (i) suppression of the LH surge and ovulation (Tafurt et al., 1980; Barnhart et al., 1997; Van Heusden et al., 2000) ; (ii) changes in permeability of cervical mucus Kumar et al., 1991) ; (iii) changes in endometrial receptivity for embryo implantation (Landgren et al., 1990; Song and Fraser, 1995; Somkuti et al., 1996) ; (iv) changes in tubal and uterine motility causing delayed gamete transport (Coutinho et al., 1973; Paltieli et al., 2000) ; and (v) a direct effect on the ovary (Dericks-Tan et al., 1992; Kim Bjorklund et al., 1992; Kuhl, 1996) . The contraceptive effects of progestins on endometrium and tubal motility are speculative.
However, in high doses used for post-coital contraception they appear to induce a potent contraceptive effect (Ling et al., 1983; Wu et al., 1999; Hapangama et al., 2001) .
A major target of progestins is to inhibit the LH surge in order to prevent ovulation. During the normal menstrual cycle there is a noticeable variation in the spontaneous pulsatile release of LH and response to a GnRH bolus (Yen et al., 1972; Wang et al., 1976) . Progesterone induces low amplitude GnRH pulses and is able to block the E 2 -induced LH surge at the hypothalamic level (Wildt et al., 1981b; Hanker et al., 1985) . Administration of progestins probably induces changes in the pulsatile release of LH comparable with the late luteal phase, although this is predominantly demonstrated in women using COCs. Two studies in progestin-only usersÐlong-term injectable depot medroxyprogesterone acetate (Perez-Lopez et al., 1975) or norethindroneenanthate (Ismail et al., 1987) Ðfailed to demonstrate differences in basal or GnRH-induced gonadotrophins compared with controls. This suggests that the pituitary is not a primary site for ovulation inhibition by these progestins. No data are available with regard to the effects of oral progestins on GnRH-stimulated pituitary response.
Although progestin-induced changes in the hypothalamic± pituitary signalling lack de®nite proof, changes in pituitary± ovarian activity are well documented. Studies performed by Landgren and co-workers (Landgren et al., 1979 (Landgren et al., , 1981 Landgren and Diczfalusy, 1980) regarding the effects of 300 mg norethisterone revealed four types of ovarian activity: (i) no activity, Other studies con®rm an unpredictable effect of norethisterone on ovulation suppression (Nuttall et al., 1982; Song et al., 1993) also when given intranasally (Shah et al., 1985; Anand Kumar et al., 1991) . Tayob con®rmed ovulation by ultrasound (Tayob et al., 1985 (Tayob et al., , 1986 and discovered a higher incidence of functional ovarian cysts in progestin-only pill users. In women using 75 mg desogestrel daily, however, complete suppression of ovulation was established while dominant follicles and moderate E 2 levels were commonly present (Rice et al., 1996; Van Heusden et al., 2000) . Data obtained from progestin implants (Norplant q , Implanon q , Uniplant q ) indicate a variable degree of ovarian activity ranging from normal ovulatory cycles, luteal phase defects, luteinized unruptured follicles and complete suppression of follicle development (Shaaban et al., 1984 (Shaaban et al., , 1993 Brache et al., 1985 Brache et al., , 2000 Alvarez et al., 1986 Alvarez et al., , 1996 Croxatto et al., 1988; Faundes et al., 1991; Shoupe et al., 1991; Barnhart et al., 1997; Devoto et al., 1997; Makarainen et al., 1998) . The high degree of ovulation inhibition achieved with progestin-only implants seems to place this strategy between oral progestin-only and injectable progestinonly contraceptive methods pertaining to contraceptive ef®cacy.
Summarizing the effects of oral progestins on the hypothalamic±pituitary ovarian axis, it seems clear that many issues remain unsolved. The direct effect of synthetic progestins on hypothalamic GnRH secretion remains poorly understood. Pituitary function is erratic and results in a wide variety of ovarian activity including ovulation. The suppression of gonadotrophins (especially LH) appears to be dependent on both dose and type of progestin. Direct effects of progestins on the ovary are suggested but remain to be established. While some progestins can achieve high contraceptive ef®cacy when ovulation suppression is almost complete, undesirable bleeding patterns seem to prevent their widespread use.
Anti-progestins
Progesterone transforms the endometrium from a proliferative to a secretory state in the normal menstrual cycle. During the late follicular phase progesterone also facilitates the LH surge, which induces ovulation (Lasley et al., 1975; Hoff et al., 1983) . Consequently, anti-progestins may also have contraceptive potential . Current knowledge of antiprogestins is derived from human and non-human studies (primates and rodents) in which different anti-progestins were used. Additional studies are needed to corroborate the data derived from animal studies and to identify disparity in the effects of different anti-progestins.
Mifepristone (RU 486), the prime example of a progesterone antagonist, is a 19-norsteroid with anti-progesterone and antiglucocorticoid properties (Bygdeman et al., 1993) . However, in certain circumstances, anti-progestins may act as progesterone agonists or anti-estrogens. Its primary use is in post-coital contraception and termination of early pregnancy (Spitz et al., 1996 ; Task Force on Postovulatory Methods of Fertility Regulation, 1999; Bygdeman et al., 2000; Spitz et al., 2000) . Anti-progestins are able to establish contraceptive effects through delay of folliculogenesis, ovulation inhibition and interference with normal endometrial development. These effects depend on dosage and phase of the menstrual cycle.
During the follicular phase, administration of anti-progestins interferes with follicle growth and ovulation in a dose-dependent fashion. Single doses of anti-progestins administered before the LH peak delay the LH surge, delay folliculogenesis and lengthen the menstrual cycle (Collins and Hodgen, 1986; Baird et al., 1995; Stratton et al., 2000) . Single or repeated administration arrests follicle development, inhibits a rise in E 2 and decreases plasma inhibin concentrations, even in low dosages Brown et al., 2002) . However, in case the delay is followed by ovulation, it does not affect implantation (Ghosh et al., 1997) . Although it is generally assumed that the principle mode of action is established through inhibition of E 2 feedback, inhibitory effects at the hypothalamus (Heikinheimo et al., 1995 (Heikinheimo et al., , 1996 Kazem et al., 1996) , the pituitary (Van Uem et al., 1989; Wolf et al., 1989; Sanchez-Criado et al., 1999) or a direct effect at the ovary (Dimattina et al., 1986; Messinis et al., 1997) have also been suggested.
Anti-progestins administered as a single high dose following the LH peak will delay development of secretory changes in the endometrium without affecting the length of the luteal phase (Kohler et al., 1984; Gemzell-Danielsson et al., 1994; Cameron et al., 1997) . This is achieved through the inhibition of progesterone-dependent down-regulation of estrogen and progesterone receptors in the endometrium (Cameron et al., 1996) . Late luteal administration of a single high dose does not achieve reliable contraceptive effects (Couzinet et al., 1990) . Very low daily doses of anti-progestins induce discrete changes in the endometrium (Danielsson et al., 1997) resulting in reduced pregnancy rates Marions et al., 1999) . Low-dose administration once a week does not inhibit ovulation, but delays endometrial development and impairs secretory activity (Gemzell- . Thus a signi®cant decrease in pregnancy rate could be established without affecting the menstrual cycle (Marions et al., 1998) even when ovulation is not consistently inhibited (Spitz et al., 1993; Katkam et al., 1995; Croxatto et al., 1998) .
Although continuous anti-progestin administration can prevent ovulation, it also affects cycle length and allows for a continuous (unopposed) in¯uence of estrogen on the endometrium. Primate studies on the anti-progestin ZK 137 316 indicate that inhibition of progesterone action together with a blockade of estrogendependent proliferation can result in endometrial atrophy . Combining progestins and anti-progestins could allow for regular cycles while maintaining anovulation. However, simultaneous and sequential cyclic co-administration of a progestin with an anti-progestin abolishes the anti-ovulatory action of the anti-progestin or the progestin (Croxatto et al., 1989;  Oral contraception and ovarian activity Cycle 2 36% Cycle 6 44% Grimes, 1994 Sunday starters >30 mm Ovulation 1 35 EE + 500/750/1000 NET (n = 10) 2 35 EE + 1000 NET (n = 11) Cycle 1 52% 10% 1 2% 3 35 EE + 500 NET (n = 11) Cycle 2 29% 5% 2 0% 4 controls (n = 10) Kekkonen et al., 1995; Kekkonen and Lahteenmaki, 1996; Van Heusden et al., 2000) but generally improves bleeding patterns.
In conclusion, the most reliable form of contraception using anti-progestins is established when given as a single high dose during the mid-cyclic phase, rendering it a rather unpractical approach. Daily doses block ovulation but may cause an unopposed estrogen effect on the endometrium, depending on the type of anti-progestin used. Low doses do not affect ovulation and delay endometrial maturation, the contraceptive effect of which lacks convincing proof.
Estrogens
It was Greenblatt who ®rst demonstrated that conjugated equine estrogens or pellets of crystalline E 2 could inhibit ovulation (Greenblatt and Zarate, 1967; Emperaire and Greenblatt, 1969; Greenblatt et al., 1974 Greenblatt et al., , 1977 . A subsequent study established the effect of different dosages of estrogen alone or in combination with a progestin on pituitary gonadotrophin release. A progressive dose-dependent suppression of LH and FSH was observed while the addition of a progestin dramatically increased the magnitude of gonadotrophin inhibition (Goldzieher et al., 1975 ). Later, s.c. E 2 implants (Magos et al., 1987) and E 2 transdermal patches (Watson et al., 1988) were also shown to be able to suppress ovulation. The exact mode of action by which estrogens induce suppression of ovulation remains to be elucidated. In castrated post-menopausal women, estrogen implants suppress gonadotrophin levels, suggesting a direct effect at the pituitary and/or hypothalamus (Thom et al., 1981) . Inhibitory and stimulatory effects of estrogens on gonadotrophin secretion (Yen and Tsai, 1971 ) along with differential effects on LH and FSH have been reported. Studies in primates suggest that the primary site of suppression of gonadotrophins is at the pituitary (Knobil, 1980) . Also in primates, estrogens were able to inhibit growth of pre-antral and medium-sized antral follicles, presumably through a direct effect at the ovary (Koering et al., 1991 (Koering et al., , 1994 .
Combined oral contraceptives
Traditionally, the doctrine with regard to the mode of action of steroidal components in COC implicated progestins to inhibit the LH surge, whereas estrogens are required for endometrial stability and thus provide satisfactory bleeding patterns. This concept is understandable from a historical perspective, since estrogens were found fortuitously as an impurity in the ®rst contraceptive medication. Currently a wide variety of changes attributed to both steroid components should contribute to the contraceptive effects of COCs. Decreased gonadotrophin secretion, inhibition of the LH surge, altered responsiveness to gonadotrophin stimulation, decreased cervical mucus permeability, decreased endometrial receptivity for implantation, decreased motility of the oviduct and uterus impairing gamete transport, or a direct suppressive effect on the ovary have all been proposed to explain the contraceptive ef®cacy of steroids. A large amount of descriptive data is available with regard to the effect of COCs on gonadotrophin and ovarian steroid levels as well as ultrasound assessments of follicular dynamics. Various investigations have been performed describing parameters of pituitary±ovarian activity during oral contraceptive regimens: alternative start of a medication-strip (Sunday starters), effect of pill omission at different moments during the pill strip, regular and extended pill-free periods and comparisons of different formulations during normal use. 
Oral contraception and ovarian activity

Normal use
The general conclusion from studies performed to investigate pituitary±ovarian activity during COC use (for overview of individual studies see Table II ) is a gradual decline of gonadotrophins in the ®rst week of medication leading to the suppression of development of non-dominant follicles and subsequent E 2 demise. In case dominant follicles are present at the start of COC, they can still increase in diameter and even reach cystic proportions (>30 mm). Delayed start of a new COC cycle (i.e.`Sunday starters') increases the risk of dominant follicles emerging and should therefore be discouraged (Killick et al., 1987; Danforth and Hodgen, 1989) . Despite increase in follicular diameter during active medication, E 2 levels eventually decrease, probably as a result of very low LH levels due to the two gonadotrophin 2-cell hypothesis (Schoot et al., 1992) . Although this raises questions with regard to`the functional life span' of these follicles (Kettel et al., 1991; Shaw et al., 1992; Faundes et al., 1996) , it appears that the potential to ovulate remains (Killick, 1989) . Virtually all commercially available COCs combine ethinylestradiol (some of the older preparations in the US still contain mestranol) with a synthetic progestin. A new combination containing 1 mg micronized 17-b-estradiol (1 mg E 2 + 150 mg desogestrel) has been shown to inhibit ovulation (Schubert and Cullberg, 1987; Wenzl et al., 1993; Csemiczky et al., 1996) . The additional contraceptive effect of E 2 remains to be established since 75 mg desogestrel alone also appears to be able to inhibit ovulation effectively (Van Heusden et al., 2000) . The extent of pituitary±ovarian suppression appears to be related to the dose of ethinyl-estradiol in COCs while the type of progestin is less important (Spellacy et al., 1980; Mall Haefeli et al., 1991; Fauser and Van Heusden, 1997; Van Heusden and Fauser, 1999) .
Pill omissions
The effect of pill omissions during COC use is related to the moment in the pill cycle and the number of pills missed (for summaries of relevant studies see Table III ). Suppression of pituitary±ovarian activity increases with the number of pills already taken and maximum suppression is often encountered at the end of the COC cycle (Smith et al., 1986) . High-dosed COCs may reach maximum suppression after only 7 days (Van Heusden et al., 2002) . Once maximum suppression is achieved, up to seven pills can be omitted (i.e. the pill-free period). Extending these 7 days easily leads to the development of dominant follicles that continue to grow, even when OC therapy is recommenced (see also Figure 1 ). The administration of hCG was able to induce ovulation and luteinization in these women (Killick, 1989) . However, the initial LH peak after stopping COC occurred 21±28 days thereafter (Klein and Mishell, 1977) . This effect may be ethinyl-estradiol dose-related (Bracken et al., 1990) . Determination of the moment of maximum suppression of pituitary±ovarian activity during any COC regimen is therefore mandatory to allow safe instructions for women who omit pills (Molloy et al., 1985; Guillebaud, 1987) . The high prevalence of pill omissions (up to 27% in 3 months) (Finlay and Scott, 1986; Klitsch, 1991) and the subsequent risk of contraceptive failure (Fraser and Jansen, 1983; Grady et al., 1986; Trussell and Kost, 1987) indicate the necessity of increasing contraceptive safety to cope with the problem of pill omissions.
The pill-free period
The standard regimen of COCs allows for a pill-free (or at least steroid-free) interval of generally 7 days for eliciting regular withdrawal bleedings. During this period, pituitary±ovarian Figure 1 . Schematic representation of changes over time in serum FSH concentrations and ovarian follicles comparing the luteo-follicular transition in normoovulatory women (upper panel) and the pill-free period in COC users (bottom panel). For further detailed description and background information with regard to follicle recruitment, selection and dominance see Fauser and Van Heusden, 1997. activity recovers following the waning inhibitory effects of contraceptive steroids. Consequently, gonadotrophin-dependent follicle growth is initiated until the beginning of the next medication strip, after which inhibition of the pituitary±ovarian axis is re-established. Events during the pill-free period resemble those observed during the early follicular phase of the normal menstrual cycle (Figure 1 ). FSH levels increase above the threshold for ovarian stimulation allowing gonadotrophin-dependent follicle growth and subsequent estrogen production (Fauser and Van Heusden, 1997; Macklon and Fauser, 2000) . Single dominant follicle development in the normal menstrual cycle coincides with a decrease in serum FSH concentrations (Pache et al., 1990; van Santbrink et al., 1995) .
Resumption of contraceptive medication at the end of the pillfree period decreases FSH levels irrespective of whether dominant follicles are present or not. If no dominant follicles are present, complete suppression of folliculogenesis ensues providing optimal contraceptive safety. Should dominant follicle selection have occurred during the pill-free period, follicle growth is likely to continue during OC treatment (Van Heusden and Fauser, 1999; Van Heusden et al., 2002) . Under these circumstances contraceptive ef®cacy depends on prevention of ovulation achieved through LH-surge inhibition. The decrease in the estrogen content of low-dose COCs therefore increases the risk of the development of dominant follicles during the pill-free period. Either reduced pituitary±ovarian suppression at the beginning of the pill-free period or less suppression at the beginning of a new OC cycle allows for an increased duration of the FSH window resulting in dominant follicle development (see Figure 1 ). Consequently, a further reduction of the estrogen dose in COCs should be accompanied a change in the paradigm of a 7 day steroid-free interval (Van Heusden and Fauser, 1996) . Shortening of the pill-free period by increasing the number of contraceptive pills per cycle (Spona et al., 1996a) or adding estrogen-only pills (Killick et al., 1998) more effectively suppresses the recovery of pituitary±ovarian activity and may therefore increase the contraceptive ef®cacy of sub-30 COCs. Some strategies to reduce the pituitary±ovarian activity during the pill-free period are summarized in Figure 2 . A summary of studies on pituitary±ovarian activity in normal pill-free periods is given in Table IV , and in extended pill-free periods in Table V . Tayob, 1990 Several low-dose COCs (n = 120) 23% 
Interventions during COC
Especially in COC users, baseline gonadotrophin levels as well as concentrations following the administration of GnRH are used to assess the magnitude of negative steroid feedback at the hypothalamic±pituitary level. However, the interpretation of these ®ndings is not without dif®culties due to the assumption that a diminished gonadotrophin response following GnRH administration should solely represent suppression by the contraceptive steroids. However, the response of the pituitary to a bolus dose of GnRH is also dependent on previous endogenous GnRH stimulation (also referred to as a`priming effect') (Wildt et al., 1981a) . The prevention of ovulation in COC is thought to occur primarily by interfering with GnRH release (Schally et al., 1970) . Proof of this contention is brought about by the notion that the contraceptive effect of COC can be reversed by administering GnRH. Although GnRH administration should result in an increase of LH and FSH, levels are lower suggesting an inhibitory effect of COCs at both the hypothalamus and the pituitary level. A direct effect on the pituitary is also suggested since repeated GnRH administration does not always result in an LH and FSH response (De Leo et al., 1991) .
Pituitary suppression appears to be unrelated to the age of the women and duration of COC use (Scott et al., 1978a) , but is dependent on the amount and type of progestin (Rommler et al., 1982; Hemrika et al., 1993) and the amount of ethinyl-estradiol (Scott et al., 1978b) . Furthermore, suppression of basal and GnRH-stimulated gonadotrophin release is time-dependent, i.e. lower doses need more time to establish suppression (Kuhl et al., 1982 (Kuhl et al., , 1984 Rommler et al., 1985) . The suppressive effect on basal and stimulated gonadotrophin release is also present in the ®rst days of the pill-free period (Rubinstein et al., 1978) . Administration of several doses of recombinant FSH during high-dose COC use resulted in dose-dependent follicle growth despite extremely low LH levels (Van Heusden et al., 2002) . Dominant follicles remained present following discontinuation of FSH and ongoing OC treatment suggesting that a direct effect, if any, of contraceptive steroids on dominant follicle growth is negligible. Once preovulatory follicles are present during COC use, the administration of either a GnRH analogue (Elomaa and Lahteenmaki, 1999) or hCG (Killick, 1989) can induce ovulation.
Interpretation of pituitary±ovarian activity during steroid contraception
Many studies concerning pituitary±ovarian activity during steroid contraception are seriously devalued in their relevance due to study design and/or interpretation of results. Infrequent (once per cycle) or conditional monitoring (`when a follicle of >12 mm appears') in most studies allows for major under-reporting of relevant events related to residual ovarian activity during steroid contraception. Despite early knowledge concerning the moment of ovulation in COC cycles, many studies focus on the second part of the cycle to assess ovulation. Obviously, the use of different assessments (urinary estrogens versus serum E 2 ), hormone assays, sampling intervals and transvaginal or transabdominal ultrasound (Belaisch-Allart et al., 1991) further reduce the possibility of comparing results. Moreover, large intra-and inter-individual differences are present in contraceptive steroid serum levels, pharmacokinetics and pharmacodynamics (Jung-Hoffmann and Kuhl, 1990; Shaw et al., 1992; Fitzgerald et al., 1994) . The origin of these differences and their consequences remain largely unexplained.
In several studies the occurrence of ovulation as a parameter of contraceptive ef®cacy is based upon serum progesterone levels. Different cut-off levels are used: >3 ng/ml (Kuhl et al., 1985; Westcombe et al., 1988) , >4 ng/ml (Chowdhury et al., 1980) , >5 ng/ml (Rabe et al., 1997) or >16 nmol/l (Song et al., 1993) and >25 nmol/l (Fitzgerald et al., 1994) . However, the assessment of ovulation based on progesterone levels may be of limited signi®cance in evaluating the contraceptive properties of COCs. A rise in progesterone concentration in serum merely indicates luteal activity and hence is unable to discriminate between ovulation, premature luteinization or luteinized unruptured follicles. It is also speculative whether progesterone levels will always rise following ovulation during COC use. Progesterone production requires both FSH and LH, which may be suppressed to such an extent that normal steroid biosynthesis by the corpus luteum is compromised.
Classi®cations combining ultrasound assessments of follicle development (diameter, signs of ovulation) and hormonal parameters have been proposed (Landgren and Diczfalusy, 1980; Hoogland and Skouby, 1993; Van Heusden and Fauser, 1996) and used or modi®ed by others (Fitzgerald et al., 1994; Van der Does et al., 1995; Spona et al., 1996b) . This method simpli®es comparison between medications, studied cycles and individuals. A classi®cation involves establishment of maximum ovarian activity during a studied cycle. However, relevant information is lost with regard to the timing of this event during the COC cycle. Furthermore, some ®ndings (e.g. when ultrasound assessments and endocrine assessment differ) remain unclassi®able (Barbosa et al., 1990) . Currently, there is no commonly accepted classi®cation.
Benchmarking for different forms of steroid contraception requires the assessment of a combination of ultrasound and hormonal parameters, frequent sampling and a study design that allows for comparison and clinical application. We propose a design involving objective veri®able criteria for future use in studies with regard to pituitary±ovarian activity and COC use which allows for maximum clinical usefulness (Figure 3 ).
Conclusions
The concomitant administration of estrogens and progestins renders it dif®cult to evaluate the individual contribution of each entity with regard to suppression of the hypothalamic±pituitary± ovarian axis. However, effects of combined oral contraceptives have proven to be more than the sum of effects induced by either estrogens or progestins alone.
Many studies have been performed, but comparison is often hampered by suboptimal design or incomplete results. No study design has yet evolved as a benchmark for contraceptive reliability. Although inhibition of follicle growth and ovulation is well understood, little is known with regard to the effects of contraceptive steroids on other systems controlling gonadotrophin secretion.
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